Crucell's press releases
are available via an RSS feed. To add this RSS feed to your reader, right click on the RSS button, click "Copy Shortcut" and add the URL to your feed reader.
Crucell announces STAR(TM) Research License Agreement
Leiden, The Netherlands, April 6, 2006- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX) announced today that it has signed a non-exclusive STAR(TM) research license agreement for the production of monoclonal antibodies with Cambridge, Massachusetts-based Millennium Pharmaceuticals Corporation. Financial details were not disclosed.
Click below for a PDF version of this press release: